Torch™ has not yet been submitted to FDA for review of its Indications for Use and is therefore NOT suitable for clinical use.
Voximetry, founded in Madison, WI in 2016, is an early stage healthcare technology company that specializes in commercializing improvements related to nuclear medicine dosimetry. Voximetry’s patient-specific approach can accurately predict efficacy and adverse effects of radiopharmaceutical therapy, thereby improving patient outcomes. Voximetry leverages intellectual property developed at the University of Wisconsin - Madison, which has a rich history of fostering successful biotechnology companies.
3/8/2021 - Read More>>
1/19/2021 - Voximetry continues its momentum with hiring of Chief Executive Officer Dr. Sue Wallace. Read More>>
11/9/2020 - Voximetry and the Imaging and Radiation Oncology Core (IROC) have reached agreement to evaluate the role of dosimetry in alpha- and beta-emitting Radiopharmaceutical Therapy (RPT) clinical trials. Read more>>
11/3/2020 - Sankara Hari Gopalakrishnan has joined Voximetry as a Senior Software Engineer for Image Processing and Optimization Algorithms. He will be advancing Voximetry's Torch™ software in the areas of deformable registration, contour propagation, and optimization. Read more>>
10/15/2020 - Voximetry has been awarded a Phase II Small Business Innovation Research (SBIR) grant valued at $1.8 million from the National Cancer Institute (NCI). This award will assist Voximetry in commercializing its Torch™ software for RPT treatment planning. Read more>>
Copyright © 2021 Voximetry Incorporated - All Rights Reserved.